Abaloparatide
Clinical data | |
---|---|
Routes of administration | Subcutaneous injection |
ATC code | none |
Legal status | |
Legal status |
|
Identifiers | |
| |
Synonyms | BA058, BIM-44058 |
CAS Number | 247062-33-5 |
PubChem (CID) | 76943386 |
ChemSpider | 34443170 |
UNII | AVK0I6HY2U |
Chemical and physical data | |
Formula | C174H299N56O49 |
Molar mass | 3,959.65 g·mol−1 |
3D model (Jmol) | Interactive image |
| |
|
Abaloparatide is a parathyroid hormone-related protein (PTHrP) analog drug in development for treating osteoporosis.[1] Like the related drug teriparatide, and unlike bisphosphonates, it is an anabolic (i.e., bone growing) agent.[2]
A subcutaneous injection formulation of the drug has completed a Phase III trial for osteoporosis.[3] This single study found a decrease in fractures.[4] A transdermal patch is also in development.[2]
References
- ↑ http://www.genengnews.com/gen-news-highlights/radius-raises-26-75m-for-phase-iii-osteoporosis-trial/81245990/
- 1 2 H. Spreitzer (18 January 2016). "Neue Wirkstoffe – Abaloparatid". Österreichische Apothekerzeitung (in German) (2/2016): 12.
- ↑ Clinical trial number NCT01343004 for "Phase III Study to Evaluate the Safety and Efficacy of BA058 for Prevention of Fracture in Postmenopausal Women" at ClinicalTrials.gov
- ↑ Miller, PD; Hattersley, G; Riis, BJ; Williams, GC; Lau, E; Russo, LA; Alexandersen, P; Zerbini, CA; Hu, MY; Harris, AG; Fitzpatrick, LA; Cosman, F; Christiansen, C; ACTIVE Study, Investigators. (16 August 2016). "Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.". JAMA. 316 (7): 722–33. PMID 27533157.
This article is issued from Wikipedia - version of the 10/26/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.